Danaher Reports First Quarter 2025 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Oracle shares drop on AI spending concerns and Microsoft criticism
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Danaher (DHR) PT Lowered to $260 at JPMorgan
April 22, 2025 1:45 PM EDTJPMorgan analyst Tycho W. Peterson lowered the price target on Danaher (NYSE: DHR) to $260.00 (from $280.00) while maintaining a Overweight rating.
The analyst comments "Like we noted in our first take earlier this morning, 1Q25 results (PR/Presentation/non-GAAP recs/Earnings supplement/10-Q) came in above expectations with notable performance in bioprocessing, while 2025 topline guidance was reiterated and bottom line guidance initiated bracketing the Street. 1Q non-GAAP core revenue growth was flat (vs. Street of -2.3% and guide of -LSD) as bioprocessing revenue grew +HSD in 1Q (consumables +LDD) with... More



